Company intelligence / Profile preview

Nimble Diagnostics

Barcelona, Catalonia, Spain

Ownership: Private
Development stage: Other

Overview

The Nimble System has demonstrated exceptional sensitivity (100%) and specificity (90%) in real-time detection of stent malfunction in large animal models, with accuracy confirmed by histology and clinical thresholds. The system is ready for human clinical validation and regulatory submissions in 2025, aiming for CE marking and FDA approval.[6]

Therapeutic areas: NephrologyPulmonologyCardiovascular
Modalities: Device
Industry: Physiological Monitoring

Partnerships

Germans Trias i Pujol Research Institute (IGTP)Universitat Politècnica de Catalunya – BarcelonaTech (UPC)Universitat de Barcelona (UB)

Beyond the preview

Go deeper on Nimble Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nimble Diagnostics.

Explore the full profile